Brief: Bioinvent Receives FDA Orphan Drug Designation For Bi-1808

BioInvent International AB

20/03/2025 07:02

March 20 (Reuters) - BioInvent International AB BINV.ST:

BIOINVENT RECEIVES FDA ORPHAN DRUG DESIGNATION FOR BI-1808 FOR THE TREATMENT OF T-CELL LYMPHOMA

FDA GRANTS ORPHAN DRUG DESIGNATION FOR BIOINVENT'S BI-1808

Source text: ID:nMFN4tSCcW

Further company coverage: BINV.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))